Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.02
HLS's Cash-to-Debt is ranked lower than
99% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 0.40 vs. HLS: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
HLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.09 Max: N/A
Current: 0.02
Equity-to-Asset 0.17
HLS's Equity-to-Asset is ranked lower than
89% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. HLS: 0.17 )
Ranked among companies with meaningful Equity-to-Asset only.
HLS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.25 Max: 0.69
Current: 0.17
-0.77
0.69
Interest Coverage 3.86
HLS's Interest Coverage is ranked lower than
73% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.17 vs. HLS: 3.86 )
Ranked among companies with meaningful Interest Coverage only.
HLS' s Interest Coverage Range Over the Past 10 Years
Min: 0.82  Med: 3.51 Max: 4.8
Current: 3.86
0.82
4.8
Piotroski F-Score: 7
Altman Z-Score: 1.52
Beneish M-Score: -2.83
WACC vs ROIC
3.34%
11.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.54
HLS's Operating Margin % is ranked higher than
83% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 7.71 vs. HLS: 17.54 )
Ranked among companies with meaningful Operating Margin % only.
HLS' s Operating Margin % Range Over the Past 10 Years
Min: 10.83  Med: 18.53 Max: 22.19
Current: 17.54
10.83
22.19
Net Margin % 6.91
HLS's Net Margin % is ranked higher than
61% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 4.84 vs. HLS: 6.91 )
Ranked among companies with meaningful Net Margin % only.
HLS' s Net Margin % Range Over the Past 10 Years
Min: 4.96  Med: 9.88 Max: 48.3
Current: 6.91
4.96
48.3
ROE % 35.94
HLS's ROE % is ranked higher than
95% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 9.89 vs. HLS: 35.94 )
Ranked among companies with meaningful ROE % only.
HLS' s ROE % Range Over the Past 10 Years
Min: 33.47  Med: 62.72 Max: 1149.06
Current: 35.94
33.47
1149.06
ROA % 5.51
HLS's ROA % is ranked higher than
56% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 4.66 vs. HLS: 5.51 )
Ranked among companies with meaningful ROA % only.
HLS' s ROA % Range Over the Past 10 Years
Min: 4.58  Med: 8.44 Max: 44.36
Current: 5.51
4.58
44.36
ROC (Joel Greenblatt) % 43.33
HLS's ROC (Joel Greenblatt) % is ranked higher than
72% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 21.13 vs. HLS: 43.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HLS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.72  Med: 44.99 Max: 51.02
Current: 43.33
13.72
51.02
3-Year Revenue Growth Rate 18.50
HLS's 3-Year Revenue Growth Rate is ranked higher than
84% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. HLS: 18.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HLS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.2 Max: 18.5
Current: 18.5
0
18.5
3-Year EBITDA Growth Rate 12.80
HLS's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 8.10 vs. HLS: 12.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HLS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.8 Max: 29.6
Current: 12.8
0
29.6
GuruFocus has detected 4 Warning Signs with Healthsouth Corp $HLS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HLS's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

HLS Guru Trades in Q2 2016

Joel Greenblatt 10,498 sh (New)
Columbia Wanger 3,461,221 sh (+2.26%)
Chuck Royce 183,713 sh (unchged)
Larry Robbins 7,169,780 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 1,703,976 sh (-1.11%)
Mariko Gordon 1,330,812 sh (-2.92%)
Paul Tudor Jones 10,130 sh (-21.94%)
Jim Simons 377,700 sh (-40.84%)
» More
Q3 2016

HLS Guru Trades in Q3 2016

Joel Greenblatt 83,432 sh (+694.74%)
Paul Tudor Jones 14,184 sh (+40.02%)
Larry Robbins 7,169,780 sh (unchged)
Chuck Royce 183,713 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 1,693,950 sh (-0.59%)
Mariko Gordon 1,277,235 sh (-4.03%)
Columbia Wanger 3,178,922 sh (-8.16%)
Jim Simons 328,700 sh (-12.97%)
» More
Q4 2016

HLS Guru Trades in Q4 2016

John Hussman 2,400 sh (New)
Steven Cohen 1,400 sh (New)
Jim Simons 386,900 sh (+17.71%)
Mariko Gordon 1,408,590 sh (+10.28%)
Larry Robbins 7,269,780 sh (+1.39%)
Chuck Royce 183,713 sh (unchged)
Joel Greenblatt Sold Out
Barrow, Hanley, Mewhinney & Strauss 1,647,350 sh (-2.75%)
Columbia Wanger 2,810,846 sh (-11.58%)
Paul Tudor Jones 12,200 sh (-13.99%)
» More
Q1 2017

HLS Guru Trades in Q1 2017

Joel Greenblatt 67,205 sh (New)
John Hussman 102,400 sh (+4166.67%)
Jim Simons 710,200 sh (+83.56%)
Chuck Royce 183,713 sh (unchged)
Larry Robbins Sold Out
Steven Cohen Sold Out
Columbia Wanger 2,749,989 sh (-2.17%)
Mariko Gordon 1,373,403 sh (-2.50%)
Barrow, Hanley, Mewhinney & Strauss 1,571,956 sh (-4.58%)
Paul Tudor Jones 8,200 sh (-32.79%)
» More
» Details

Insider Trades

Latest Guru Trades with HLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621498    SIC: 8093
Compare:NAS:ACHC, NYSE:CHE, NYSE:MD, NAS:LPNT, OTCPK:LTGHY, OTCPK:CAKFF, NAS:SCAI, NAS:AMED, NYSE:SEM, NYSE:AMN, NYSE:THC, NYSE:EVHC, NAS:TVTY, OTCPK:SKHCY, NYSE:CYH, NAS:LHCG, NAS:SGRY, NAS:AFAM, NYSE:USPH, NAS:WOOF » details
Traded in other countries:HSOA.Germany,
Headquarter Location:USA
Healthsouth Corp provides post -acute healthcare services. It offers facility based and home based post-acute services through network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.

Healthsouth provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. The firm operates in two segments: inpatient rehabilitation and home health and hospice. The inpatient rehabilitation segment contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas. The home health and hospital segment provides skilled home health services through agencies concentrated in the southeastern United States and Texas, which include nursing, physical, occupational, and speech therapy, social work, and hospice services.

Ratios

vs
industry
vs
history
PE Ratio 17.22
HLS's PE Ratio is ranked higher than
78% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. HLS: 17.22 )
Ranked among companies with meaningful PE Ratio only.
HLS' s PE Ratio Range Over the Past 10 Years
Min: 1.71  Med: 13.71 Max: 29.71
Current: 17.22
1.71
29.71
Forward PE Ratio 17.30
HLS's Forward PE Ratio is ranked higher than
70% of the 108 Companies
in the Global Medical Care industry.

( Industry Median: 18.73 vs. HLS: 17.30 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.22
HLS's PE Ratio without NRI is ranked higher than
80% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 28.00 vs. HLS: 17.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
HLS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.81  Med: 14.9 Max: 177.27
Current: 17.22
1.81
177.27
Price-to-Owner-Earnings 16.45
HLS's Price-to-Owner-Earnings is ranked higher than
76% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 27.48 vs. HLS: 16.45 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HLS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.42  Med: 13.59 Max: 52.94
Current: 16.45
2.42
52.94
PB Ratio 5.28
HLS's PB Ratio is ranked lower than
81% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 2.65 vs. HLS: 5.28 )
Ranked among companies with meaningful PB Ratio only.
HLS' s PB Ratio Range Over the Past 10 Years
Min: 4.58  Med: 7.82 Max: 189.01
Current: 5.28
4.58
189.01
PS Ratio 1.29
HLS's PS Ratio is ranked higher than
62% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. HLS: 1.29 )
Ranked among companies with meaningful PS Ratio only.
HLS' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.14 Max: 3.95
Current: 1.29
0.4
3.95
Price-to-Free-Cash-Flow 11.24
HLS's Price-to-Free-Cash-Flow is ranked higher than
85% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. HLS: 11.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HLS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.77  Med: 9.91 Max: 18.1
Current: 11.24
1.77
18.1
Price-to-Operating-Cash-Flow 7.44
HLS's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 14.15 vs. HLS: 7.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HLS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.53  Med: 6.72 Max: 11.6
Current: 7.44
1.53
11.6
EV-to-EBIT 10.98
HLS's EV-to-EBIT is ranked higher than
89% of the 292 Companies
in the Global Medical Care industry.

( Industry Median: 18.39 vs. HLS: 10.98 )
Ranked among companies with meaningful EV-to-EBIT only.
HLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.5  Med: 11.1 Max: 39.7
Current: 10.98
-25.5
39.7
EV-to-EBITDA 8.65
HLS's EV-to-EBITDA is ranked higher than
82% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 13.46 vs. HLS: 8.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
HLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.8  Med: 8.9 Max: 23.2
Current: 8.65
-43.8
23.2
PEG Ratio 1.20
HLS's PEG Ratio is ranked higher than
88% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 3.11 vs. HLS: 1.20 )
Ranked among companies with meaningful PEG Ratio only.
HLS' s PEG Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.42 Max: 2.13
Current: 1.2
1.04
2.13
Shiller PE Ratio 12.60
HLS's Shiller PE Ratio is ranked higher than
96% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 28.31 vs. HLS: 12.60 )
Ranked among companies with meaningful Shiller PE Ratio only.
HLS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.33  Med: 17.37 Max: 247.88
Current: 12.6
11.33
247.88
Current Ratio 1.40
HLS's Current Ratio is ranked higher than
53% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. HLS: 1.40 )
Ranked among companies with meaningful Current Ratio only.
HLS' s Current Ratio Range Over the Past 10 Years
Min: 0.6  Med: 2.2 Max: 10.68
Current: 1.4
0.6
10.68
Quick Ratio 1.40
HLS's Quick Ratio is ranked higher than
57% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. HLS: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
HLS' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.96 Max: 10.68
Current: 1.4
0.6
10.68
Days Sales Outstanding 43.08
HLS's Days Sales Outstanding is ranked lower than
55% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. HLS: 43.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
HLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.54  Med: 44.27 Max: 49.69
Current: 43.08
40.54
49.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.07
HLS's Dividend Yield % is ranked higher than
63% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. HLS: 2.07 )
Ranked among companies with meaningful Dividend Yield % only.
HLS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.5  Med: 2 Max: 2.83
Current: 2.07
0.5
2.83
Dividend Payout Ratio 0.35
HLS's Dividend Payout Ratio is ranked higher than
94% of the 146 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. HLS: 0.35 )
Ranked among companies with meaningful Dividend Payout Ratio only.
HLS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.36 Max: 0.46
Current: 0.35
0.14
0.46
3-Year Dividend Growth Rate 37.70
HLS's 3-Year Dividend Growth Rate is ranked higher than
87% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 11.70 vs. HLS: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
HLS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 37.7
Current: 37.7
0
37.7
Forward Dividend Yield % 2.05
HLS's Forward Dividend Yield % is ranked higher than
60% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 1.84 vs. HLS: 2.05 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.07
HLS's 5-Year Yield-on-Cost % is ranked higher than
50% of the 311 Companies
in the Global Medical Care industry.

( Industry Median: 2.23 vs. HLS: 2.07 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
HLS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.5  Med: 2 Max: 2.83
Current: 2.07
0.5
2.83
3-Year Average Share Buyback Ratio -0.40
HLS's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. HLS: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.5  Med: 1 Max: 0
Current: -0.4
-37.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.90
HLS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 89 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. HLS: 0.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HLS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.42  Med: 1.32 Max: 108.06
Current: 0.9
0.42
108.06
Price-to-Median-PS-Value 1.08
HLS's Price-to-Median-PS-Value is ranked higher than
52% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. HLS: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HLS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.11 Max: 3.41
Current: 1.08
0.41
3.41
Price-to-Peter-Lynch-Fair-Value 1.26
HLS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
79% of the 47 Companies
in the Global Medical Care industry.

( Industry Median: 2.13 vs. HLS: 1.26 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
HLS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.1  Med: 1.41 Max: 5.91
Current: 1.26
0.1
5.91
Earnings Yield (Greenblatt) % 9.12
HLS's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 334 Companies
in the Global Medical Care industry.

( Industry Median: 4.98 vs. HLS: 9.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HLS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 8.7 Max: 15.8
Current: 9.12
2.5
15.8
Forward Rate of Return (Yacktman) % 20.27
HLS's Forward Rate of Return (Yacktman) % is ranked higher than
76% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. HLS: 20.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HLS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.2  Med: 15.3 Max: 26.7
Current: 20.27
3.2
26.7

More Statistics

Revenue (TTM) (Mil) $3,711
EPS (TTM) $ 2.68
Beta0.15
Short Percentage of Float10.14%
52-Week Range $36.97 - 47.89
Shares Outstanding (Mil)89.57

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,926 4,162 4,419
EPS ($) 2.69 2.93 3.25
EPS without NRI ($) 2.69 2.93 3.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.96 0.96 0.96
» More Articles for HLS

Headlines

Articles On GuruFocus.com
HealthSouth Issues Notice Of Intent To Redeem Its 2.00% Convertible Senior Subordinated Notes Due 20 May 26 2017 
HealthSouth Declares Dividend on Common Stock May 04 2017 
HealthSouth Supports Therapy Research Through Grant Program May 02 2017 
HealthSouth To Participate In The UBS Global Healthcare Conference May 01 2017 
HealthSouth Announces Date Of 2017 First Quarter Earnings Conference Call Apr 05 2017 
HealthSouth Corporation and Memorial Hospital at Gulfport Launch Joint Venture to Own and Operate In Apr 03 2017 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
26.25% Annual Return With Lobbying Stocks? Here Is How It Works Nov 21 2014 
5 Stocks Building Long-Term Wealth With Increased Dividends Jul 28 2014 
"Thrift, fearlessness, resilience, hard work" - What Makes Mariko Gordon Our Newest Guru Dec 07 2013 

More From Other Websites
HealthSouth Issues Notice Of Intent To Redeem Its 2.00% Convertible Senior Subordinated Notes Due... May 26 2017
Thinly Traded Health Care Stock Tries To Resuscitate New Breakout May 24 2017
ETFs with exposure to HealthSouth Corp. : May 19, 2017 May 19 2017
HealthSouth Corp. :HLS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 May 18 2017
HealthSouth Declares Dividend on Common Stock May 04 2017
HealthSouth Supports Therapy Research Through Grant Program May 02 2017
Edited Transcript of HLS earnings conference call or presentation 28-Apr-17 1:00pm GMT May 01 2017
HealthSouth To Participate In The UBS Global Healthcare Conference May 01 2017
HealthSouth Corp (HLS) Looks Good: Stock Moves 8% Higher May 01 2017
HealthSouth Soars to 52-Week High After Better-Than-Expected Q1 Results Apr 28 2017
HealthSouth beats Street 1Q forecasts Apr 27 2017
HealthSouth Reports Strong Revenue and Earnings Growth for First Quarter 2017 and Reiterates... Apr 27 2017
HealthSouth Announces Date Of 2017 First Quarter Earnings Conference Call Apr 05 2017
HealthSouth Corporation and Memorial Hospital at Gulfport Launch Joint Venture to Own and Operate... Apr 03 2017
Cleveland Clinic CEO: Must cut cost of covering people Mar 28 2017
Soon-to-open Pearland rehab hospital names CEO Mar 27 2017
HealthSouth to Hold Annual Stockholder Meeting Mar 24 2017
PHOTOS: Mount Carmel aims for greater rehabilitation market share when HealthSouth joint venture... Mar 23 2017
Is HealthSouth a Suitable Stock for Value Investors? Mar 21 2017
HUNTSVILLE HOSPITAL, AL -- Moody's affirms Huntsville Health Care Authority's A1 and P1; Outlook... Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)